256 related articles for article (PubMed ID: 9007853)
61. The novel alpha 2-adrenoceptor agonist [3H]mivazerol binds to non-adrenergic binding sites in human striatum membranes that are distinct from imidazoline receptors.
Flamez A; Gillard M; De Backer JP; Vauquelin G; Noyer M
Neurochem Int; 1997 Jul; 31(1):125-9. PubMed ID: 9185172
[TBL] [Abstract][Full Text] [Related]
62. [125I]2-(2-chloro-4-iodo-phenylamino)-5-methyl-pyrroline (LNP 911), a high-affinity radioligand selective for I1 imidazoline receptors.
Greney H; Urosevic D; Schann S; Dupuy L; Bruban V; Ehrhardt JD; Bousquet P; Dontenwill M
Mol Pharmacol; 2002 Jul; 62(1):181-91. PubMed ID: 12065769
[TBL] [Abstract][Full Text] [Related]
63. Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands.
Boronat MA; Olmos G; García-Sevilla JA
Br J Pharmacol; 1998 Sep; 125(1):175-85. PubMed ID: 9776358
[TBL] [Abstract][Full Text] [Related]
64. Region-dependent effects of acute and chronic tranylcypromine in vivo on [3H]2-BFI binding to brain imidazoline I(2) sites.
MacInnes N; Handley SL
Eur J Pharmacol; 2001 Oct; 428(2):221-5. PubMed ID: 11675039
[TBL] [Abstract][Full Text] [Related]
65. The relationship between density of alpha-adrenoceptor binding sites and contractile responses in several porcine isolated blood vessels.
Wright IK; Blaylock NA; Kendall DA; Wilson VG
Br J Pharmacol; 1995 Feb; 114(3):678-88. PubMed ID: 7735695
[TBL] [Abstract][Full Text] [Related]
66. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites.
Carpéné C; Collon P; Remaury A; Cordi A; Hudson A; Nutt D; Lafontan M
J Pharmacol Exp Ther; 1995 Feb; 272(2):681-8. PubMed ID: 7853182
[TBL] [Abstract][Full Text] [Related]
67. Pharmacologic characterization of imidazoline receptor proteins identified by immunologic techniques and other methods.
Escribá PV; Ozaita A; García-Sevilla JA
Ann N Y Acad Sci; 1999 Jun; 881():8-25. PubMed ID: 10415892
[TBL] [Abstract][Full Text] [Related]
68. Development of a high-affinity radioiodinated ligand for identification of imidazoline/guanidinium receptive sites (IGRS): intratissue distribution of IGRS in liver, forebrain, and kidney.
Ivkovic B; Bakthavachalam V; Zhang W; Parini A; Diz D; Bosch S; Neumeyer JL; Lanier SM
Mol Pharmacol; 1994 Jul; 46(1):15-23. PubMed ID: 8058049
[TBL] [Abstract][Full Text] [Related]
69. Modulation of MAO activity by imidazoline and guanidine derivatives.
Raasch W; Muhle H; Dominiak P
Ann N Y Acad Sci; 1999 Jun; 881():313-31. PubMed ID: 10415932
[TBL] [Abstract][Full Text] [Related]
70. High-affinity binding of beta-carbolines to imidazoline I2B receptors and MAO-A in rat tissues: norharman blocks the effect of morphine withdrawal on DOPA/noradrenaline synthesis in the brain.
Miralles A; Esteban S; Sastre-Coll A; Moranta D; Asensio VJ; García-Sevilla JA
Eur J Pharmacol; 2005 Aug; 518(2-3):234-42. PubMed ID: 16061219
[TBL] [Abstract][Full Text] [Related]
71. Structural and ligand recognition properties of imidazoline binding proteins in tissues of rat and rabbit.
Lanier B; Raddatz R; Bakthavachalam V; Coupry I; Neumeyer JL; Lanier SM
Mol Pharmacol; 1995 Oct; 48(4):703-10. PubMed ID: 7476897
[TBL] [Abstract][Full Text] [Related]
72. Imidazoline/guanidinium binding sites and their relation to inhibition of K(ATP) channels in pancreatic B-cells.
Rustenbeck I; Herrmann C; Ratzka P; Hasselblatt A
Naunyn Schmiedebergs Arch Pharmacol; 1997 Sep; 356(3):410-7. PubMed ID: 9303581
[TBL] [Abstract][Full Text] [Related]
73. A search for presynaptic imidazoline receptors at rabbit and rat noradrenergic neurones in the absence of alpha 2-autoinhibition.
Gaiser EG; Trendelenburg AU; Starke K
Naunyn Schmiedebergs Arch Pharmacol; 1999 Feb; 359(2):123-32. PubMed ID: 10048597
[TBL] [Abstract][Full Text] [Related]
74. Characterization of [3H]idazoxan binding proteins in solubilized membranes from rabbit and human liver.
Remaury A; Missy K; Parini A
J Auton Nerv Syst; 1998 Oct; 72(2-3):111-7. PubMed ID: 9851559
[TBL] [Abstract][Full Text] [Related]
75. Down-regulation of imidazoline sites in rabbit kidney.
Hamilton CA; Jardine E; Reid JL
Eur J Pharmacol; 1993 Oct; 243(1):95-7. PubMed ID: 7902815
[TBL] [Abstract][Full Text] [Related]
76. The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites.
Chan SL; Brown CA; Scarpello KE; Morgan NG
Br J Pharmacol; 1994 Aug; 112(4):1065-70. PubMed ID: 7952865
[TBL] [Abstract][Full Text] [Related]
77. Distribution of nonadrenergic [3H]rilmenidine binding in rat brain and kidney.
King PR; Suzuki S; Louis WJ; Gundlach AL
Ann N Y Acad Sci; 1995 Jul; 763():194-207. PubMed ID: 7677331
[No Abstract] [Full Text] [Related]
78. Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes.
Piletz JE; Zhu H; Chikkala DN
J Pharmacol Exp Ther; 1996 Nov; 279(2):694-702. PubMed ID: 8930173
[TBL] [Abstract][Full Text] [Related]
79. Comparison of the interaction of agmatine and crude methanolic extracts of bovine lung and brain with alpha 2-adrenoceptor binding sites.
Pinthong D; Hussain JF; Kendall DA; Wilson VG
Br J Pharmacol; 1995 Jun; 115(4):689-95. PubMed ID: 7582492
[TBL] [Abstract][Full Text] [Related]
80. Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain.
Mallard NJ; Hudson AL; Nutt DJ
Br J Pharmacol; 1992 Aug; 106(4):1019-27. PubMed ID: 1356565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
